Niraparib almost quadrupled progression-free survival times in certain ovarian cancer patients compared to placebo, according to results from a Phase III trial.

In patients with germline BRCA mutations, niraparib, a PARP inhibitor developed by Tesaro, demonstrated a PFS of 21.0 months, compared to 5.5 months with placebo.

Niraparib also significantly improved PFS in patients with non-germline BRCA mutations, with a median of 9.3 months compared to 3.9 in the control group. In patients who were not germline BRCA mutation carriers, but whose tumors were determined to be HRD-positive, niraparib extended PFS to 12.9 months compared to 3.8 months with placebo.